5956 Sherry Lane
Suite 650
Dallas, TX 75225
United States
972 687 7250
https://www.swkhold.com
Sector(s): Financial Services
Industry: Asset Management
Full-time employees: 23
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Jody. D Staggs | CEO & President | 953.15k | N/A | 1982 |
David R. Earhart | General Counsel & Secretary | N/A | N/A | N/A |
Mr. John David Tamas | Director of Underwriting | N/A | N/A | N/A |
SWK Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. This segment also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. The Pharmaceutical Development segment provides customers pharmaceutical development, formulation, and manufacturing services, as well as formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform. It also offers intellectual property licensing business. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was incorporated in 1996 and is headquartered in Dallas, Texas.
SWK Holdings Corporation’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 6; Compensation: 7.